Following initial characterization of the reference human genome, initiatives have evolved worldwide to identify genomic aberrations in cancer with the aim of deriving diagnostic, prognostic and predictive information. However, the functional and clinical relevance of many somatic variants in cancer are presently unknown and there is no consensus definition of 'actionability' for genomic aberrancies. Therefore, while robust detection of a variety of genetic aberrations in clinical specimens remains a technical hurdle, the greater challenge lies in the interpretation of these alterations. Critical evaluation of genomic variation in cancer requires the integration of available clinical and preclinical evidence related to their frequencies, functions and roles as therapeutic targets. Many publicly accessible data resources have compiled such evidence to facilitate the understanding of genomic results and ultimately translating results to clinical action. Information for these data resources is derived from various sources including large population genomic datasets, curation of published literature, and data sharing by the scientific community. Currently, there is no widely accepted guidance to definitively assess and integrate the diagnostic, prognostic and predictive information of somatic variants using these knowledge databases. This review will describe data resources pertinent to the identification and interpretation of actionable genomic aberrations by clinicians, and highlight relevant issues in the clinical application of tumor molecular profiling results.
Introduction
The advent of massively parallel, next-generation sequencing (NGS) technologies has enabled the integration of cancer genomics into clinical care [1, 2] . Somatic variations can be detected by a variety of approaches including sequence analysis of the genome (DNA; includes all protein coding genes and the 98% of the genome that does not contain genes), exome (DNA; all proteincoding genes), transcriptome (RNA; all expressed genes), and epigenome (e.g. DNA methylation and histone protein modifications) [1, 3, 4] . The ensuing read-outs are often complementary and multi-'omic' profiling of tumors is increasingly implemented in large-scale molecular characterization projects, most notably the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) [5, 6] . However, clinical adoption of multi-'omic' integrated tumor profiling is not yet common in diagnostic laboratories, and targeted DNA profiling of known mutations or subsets of genes by NGS is currently the mainstay of most clinical molecular laboratories [5] .
The term "actionability" in the context of somatic variants is often applied to describe variants that have the potential to alter patient care, with nuanced meaning dependent on the clinical context and stakeholder perspective [7] . Although millions of tumor genomic aberrancies have been identified [8] , the functional and clinical relevance of many of these are unknown [7, 9] , and molecular subsets with available matching targeted therapies of proven clinical benefit comprise an even smaller proportion [7, 9] . Indeed, the distinction between actionable and nonactionable findings is neither dichotomous nor static, and the interpretation of the clinical and biological impact of somatic variants exists within a spectrum of available clinical and preclinical evidence [7, [10] [11] [12] [13] [14] [15] .
Critical evaluation of variant interpretation requires an understanding of available resources used to define clinical relevance, including limitations of the underlying data source, scope of the database, and intentions of the curators. This review will discuss data resources for the identification and interpretation of somatic variants detectable by NGS approaches, with a focus on the clinical application of tumor molecular profiling results. Table 1 provides a glossary of terms used throughout this review.
Tumor sampling, processing and laboratory identification of somatic variants
The ability to detect cancer genomic variation using NGS is highly dependent on the nature and preparation of tumor material. For clinical tumor molecular profiling, extraction from formalin-fixed, paraffin-embedded (FFPE) tissues remains a mainstay due to the widespread use of these specimens in diagnostic histopathological assessment [16, 17] . Surgical and excisional biopsy specimens generally yield amounts of DNA sufficient for the purpose of molecular characterization. The quantity and quality of tumor DNA provided by core needle biopsies, fine needle aspirates, and cell blocks from pleural or peritoneal fluid are more variable and depend largely on the size of the specimen, tumor cellularity and purity, and extent of necrosis. In addition, the degree of contamination by normal tissue as well as molecular heterogeneity within the tumor specimen may dilute and therefore limit the detection of potentially significant genomic aberrations [18, 19] . Techniques such as macrodissection or laser capture microdissection may help increase the sensitivity of detection for somatic variants by isolating cancer cells and excluding surrounding normal tissue, albeit with increased labor and cost [18] .
In general, DNA analysis by NGS can be broken down into the following parts: DNA isolation, optional target enrichment, library construction, sequence data generation, read alignment, variant calling, interpretation, and reporting [3] . The laboratory and bioinformatics aspects of these processes have been summarized in the literature [15, 20, 21] .
Annotation and reporting of variants in cancer
Once detected, genomic variants identified by NGS are assessed for clinical relevance to the initial reason for testing. In the annotation process, variants are typically first assessed against quality parameters established during test validation (such as required read depth, variant allele frequency, and quality scores) to remove those that do not meet defined quality criteria [11, 12, 17] . Once high-quality variants are identified, various databases and literature sources are used to search for previously reported information on the specific variant, in the context of the known cancer diagnosis and histology [15] .
Characteristics of databases for interpreting germline polymorphisms
To identify tumor-specific genomic aberrancies, germline DNA variants first need to be identified and subtracted. This may be done through sequencing of a patient's normal tissue [15, 17] , or alternatively if a matched (patient's own) germline DNA sample is unavailable, public databases of germline polymorphisms may be used [17, 20] . However, comparing to germline polymorphism databases may lead to the incorrect classification of germline as somatic variations [22] , and may not capture rare polymorphisms private to a family or population not yet well surveyed by large-scale genomics projects.
Databases for germline polymorphisms may be broadly categorized as population-based and locus-specific. Population-based initiatives such as 1000 Genomes [23] and the National Heart, Lung, and Blood Institute Exome Sequencing Project [24] sequence DNA in a largely unbiased way from large populations that enable analysis of the prevalence of germline polymorphisms in those groups. Information presented in locus-specific-based databases, on the other hand, are limited to variants in individual genes curated by groups of experts from published gene-specific information in the literature (e.g. OMIM [25] ) and/or voluntarily shared data from the scientific community (e.g. DECIPHER [26] and the NCBI ClinVar [27] ). Population frequency information is often not captured by locus-specific databases, although more detailed biological information on specific genes may be presented. Table 2 summarizes examples of germline variant databases and type of somatic variants covered. [28] and CIViC [29] that group somatic mutations by tumor histology and link variants to specific targeted therapies, however do not yet incorporate clinical practice guideline recommendations or rank the relevant targeted agents by regulatory approval status (Table 3) . Information presented in these knowledge databases may be curated by groups of experts from sources including large-scale genomic data sets (e.g. TCGA and ICGC) [30, 31] , published locus-specific information from the literature [30] [31] [32] , and/or voluntarily shared data from the scientific community [27, 33] . Reliance on voluntary data sharing or often-automated variant calls from large-scale genome projects, however, may result in the listing of variants that are not confirmed to be somatic in nature.
In this evolving field where novel variant data are rapidly accumulating, there are significant challenges to ensure these databases remain comprehensive and up-to-date. A recent Global Alliance for Genomics and Health (GA4GH) web-based survey of cancer sequencing initiatives worldwide showed that most combine the use of two or more annotation sources [34] , as no single database is sufficiently comprehensive to be used in isolation. Clinicians need to be cognizant of data sources used by molecular diagnostics laboratories to classify variants and to be aware of potential pitfalls in their use.
In silico tools for predicting biological effects of somatic mutations of unknown significance For novel somatic mutations not yet captured in public databases or publications, in silico tools may aid in predicting the pathogenicity of a variant. Biological features such as evolutionary conservation, predicted functional domains of the encoded protein, or potential effect on exon usage/splicing [35] are often integrated into in silico tools that score variants as to their effect on the predicted protein product (Table 4) . However, these in silico analyses are reported to have low specificity [36] , their sensitivity is genedependent [37] , and few are designed specifically for the detection of cancer-related somatic variants [38] .
Databases that catalogue the predicted biological effects of somatic mutations are evolving that include locus-specific information in the scientific literature and meta-prediction approaches (Table 5 ) [35] . Information derived through meta-prediction methods combine results from multiple predictor methods to produce a composite score of predicted pathogenicity [35] . Machine-learning methods have been integrated to further enhance meta-prediction approaches that use benchmark datasets to formulate algorithms that predict the function of variants of unknown significance [35] .
Nomenclature for somatic variants
Nomenclature for genetic variants has evolved over time. Recently published guidelines from the multidisciplinary working group convened by the Association for Molecular Pathology Table 4 . Examples of in silico tools to predict the biological effects of somatic and germline mutations Category Name URL
In silico tools Cancer-specific High-throughput Annotation of Somatic Mutations (CHASM) [38] http://wiki.chasmsoftware.org/index.php/Main_Page
Combined Annotation Dependent Depletion (CADD) [105] http://cadd.gs.washington.edu Functional Analysis Through Hidden Markov Models (FATHMM) [106] http://fathmm.biocompute.org.uk Mutation Assessor [107] http://mutationassessor.org/v1/ Polymorphism Phenotyping (Polyphen) [108] http://genetics.bwh.harvard.edu/pph2/ PON-P2 [109] http://structure.bmc.lu.se/PON-P2/ Protein Analysis Through Evolutionary Relationships (PANTHER) [110] http://pantherdb.org Screening for Non-Acceptable Polymorphisms (SNAP) [111] http://www.ngrl.org.uk/Manchester/page/snap-screeningnonacceptable-polymorphisms Sorting Intolerant From Tolerant (SIFT) [112] http://sift.jcvi.org adherence to HGVS rules can also confound comparison of these data. For these reasons, searching of variants in databases should take into account alternate nomenclature or colloquial names of variants and the likelihood of nomenclature errors present in databases.
Incidental germline findings
The use of a patient's matched normal DNA in laboratory analysis in carries the potential for the incidental identification of clinically significant germline variants [40, 41] . In cases where matched germline samples are not analyzed, certain characteristics of the tumor mutation profile may still suggest the underlying presence of germline variants [9, 22, 42] ; For instance, a hypermutated tumor may suggest an underlying DNA mismatch repair defect, while variants appearing in cancer predisposing genes that can undergo second-hit mutations such as BRCA1 and BRCA2 may indicate an inherited germline abnormality [43] . The Working Group on Incidental Findings in Clinical Exome and Genome Sequencing of the American College of Medical Genetics and Genomics have published recommendations on the sequencing and reporting of clinical germline exome and genome sequencing [41] . The guideline and its recent update [44] , emphasize the role of the ordering clinician/team in providing comprehensive pre-and post-test counseling, taking into account patient preferences, and consulting the clinical geneticist at the appropriate time [41, 44] .
Reporting of cancer molecular profiling results
Annotated somatic variant results from molecular diagnostic laboratories are provided to requesting clinicians in the form of a molecular profiling report. Some of the main challenges facing the generation, formatting and dissemination these reports arise from the rapid accumulation of novel information for identified genomic variants that may only become available following the initial return of results [45, 46] . To aid laboratory updating of novel variant information, data sharing initiatives, such as BRCA Share (formerly UMD-BRCA1 mutations database) that focuses on the classification of variants of unknown significance [47] , provides a list of variants that have been re-classified within the past 6 months to registered users [48] . However, to our knowledge no such database is currently available for somatic variants.
Furthermore, the static nature of most hospital information systems pose challenges to the provision of updated novel variant information to ordering clinicians [45, 49] . To this end, software groups such as GeneInsight Clinic have developed a web-based interface that is regularly updated to provide the most current variant information at the time of clinician access, some of which provide automatically generated physician alerts when new variant information is available [45, 46, 50] . This and similar programs can either be obtained as a standalone genetic report management system, or integrated into an existing electronic health record [45] . These software are presently geared more towards the return of germline variant information [45] , although the framework may allow for future application for somatic variants.
Another challenge facing the return of updated information for previously identified variants involve the duty to inform patients of new pathological findings, with the potential for privacy concerns and liability if the patient is no longer in the care of the initial ordering physician [49] . Presently, there is no widely accepted process to update previously disseminated genetic reports, with at times conflicting recommendations from different guidelines. For instance, the American College of Medical Genetics and Genomics recommend the development of laboratory-specific policy on genetic testing data re-analysis and the exploration of innovative approaches to allow patients and providers efficient access to updated information [12] , while the Association for Molecular Pathology (AMP) multidisciplinary working group suggested that reports remain static and that updates be provided only when specifically requested [39] . Indeed, a recent survey of the AMP membership group highlights significant differences in variant reporting practices across molecular diagnostic laboratories [39] .
Molecular heterogeneity in cancer
Besides the abovementioned challenges related to the reporting of molecular profiling results, the testing of tumor tissue from a single time point underscores another limitation in current NGSbased efforts in the clinic. Increasingly, evidence from rapid autopsy studies revealed branched evolution of the cancer genome, leading to genetically distinct subclonal populations of cells that may exhibit selective advantages in cell growth, metastatic potential, and treatment resistance [51] [52] [53] . Indeed there are significant limitations to the use of archival and/or single-time point biopsies in molecular matching of targeted therapies in cancer [51] [52] [53] . The occurrence of temporal evolution of tumor clones and subclones, especially under treatment-imposed selection pressure further compounds this issue [7, 54] . However, significant safety and feasibility issues associated with multiple tumor sampling limit the comprehensive exploration of a patient's true burden of somatic aberrancies from biopsy-based analyses. Assessment of serum circulating tumor cells and cell-free tumor DNA are promising avenues for less invasive molecular testing, with the potential for a more global assessment of the range of somatic variations from multiple metastatic lesions in an individual patient [51] [52] [53] 55] . In addition to intratumoral heterogeneity, Table 5 . Examples of databases to predict the biological effects of somatic and germline mutations Category Name URL Databases for in silico tools dbNSFP (from Variant Annotation Tools) [113] http://varianttools.sourceforge.net/Annotation/DbNSFP SNPdbe [114] https://www.rostlab.org/services/snpdbe/ another dilemma that poses challenge to clinical decision making is the co-existence of multiple driver mutations that may represent diverse therapeutic targets. If only single agent therapies are available, then prioritization may be based on factors such as allelic frequencies of variants with known functionality [19, 56] . Combinatorial therapies would be optimal in such cases to minimize therapeutic resistance.
Clinical applications of tumor molecular profiling
The past decade has seen an evolution of clinical trial designs to test the benefit and utility of genotype-drug matching [57] , the evidence for which is still actively being gathered [58, 59] . Novel designs such as basket, umbrella and hybrid trials, adapt interpretations of somatic variants identified through molecular profiling programs to guide treatment selection [57] . However, recent reported results from these initiatives have shown that only a limited proportion of patients who undergo tumor molecular profiling were enrolled in genotype-matched clinical trials (Table 6 ) [60] [61] [62] [63] . A number of reasons may account for this attrition and variation in matching rates, traversing all aspects of the treatment matching process including barriers to participation in molecular profiling initiatives, technicalities of tumor molecular profiling, identification and interpretation of actionable aberrancies, and patient and region-related factors limiting enrollment into genotype-matched trials (Figure 1 ).
Determining clinical actionability
The overlying objective of genotype-drug matching trials involves testing the clinical utility of molecularly targeted therapies in patients with "matching" somatic aberrancies. There are currently
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Genotypematched trial Figure 1 . Attrition in molecular profiling and genotype-drug matching. no accepted guidelines or a universal approach to treatment assignment. Some clinical trials such as Institut Curie's SHIVA [62] and the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) [64] employ pre-determined treatment allocation algorithms to determine the most suitable targeted agents for particular somatic variants identified. While algorithm recommendations would ideally constitute best-inclass agent targeting particular molecular aberrations, the selection of targeted therapies in these genotype-matching clinical trials may be confounded by agent accessibility. This practice is to be contrasted to clinical trials such as the Gustave Roussy Molecular Screening for Cancer Treatment Optimization (MOSCATO)-01 [61, 65] , and the Princess Margaret Cancer Centre Integrated Molecular Profiling in Advanced Cancers
Trial/Community Molecular Profiling in Advanced Caners (IMPACT/COMPACT) trial [66] , where treatment allocation is contingent on targeted agent availability through real-life early phase clinical trial setting. Table 7 describes an illustrative case study from the Princess Margaret IMPACT/COMPACT trial. The multidisciplinary cancer conference, also known as tumor board, is the hallmark of high-quality care particularly for complex cases in oncology [67] [68] [69] . Some institution-based molecular profiling and treatment matching efforts such as SHIVA [62] , MOSCATO-01 [61, 65] , the British Columbia Cancer Agency Personalized Oncogenomics [70] , and the Princess Margaret Cancer Centre IMPACT/COMPACT trial [66] incorporate a molecular tumor board that includes scientists, clinicians, medical geneticists, bioinformaticians, and molecular pathologists. In this Table 7 . Case study from the Princess Margaret IMPACT/COMPACT trial [66] . A 70-year-old female with metastatic colorectal adenocarcinoma and disease involving the lung, liver and peritoneum. The patient underwent initial palliative chemotherapy with 5-fluorouracil and oxaliplatin. On progression, this was followed by second line chemotherapy with the combination of 5-fluorouracil and irinotecan with bevacizumab, during which the patient was enrolled into the Princess Margaret IMPACT/COMPACT trial. On progression, the patient was enrolled into a clinical trial investigating the triple combination of a BRAF inhibitor, a PI3K inhibitor and an anti-EGFR monoclonal antibody, where she had stable disease for 4.5 months before progressing.
Mutations detected
Sukhai classification [15] Description BRAF c.1799T>A (p.V600E) Class 1 Approximately 8%À15% of colorectal cancers harbor BRAF mutations, of which 47%À96% are BRAF V600E [118] . This mutation is associated with poorer prognosis in colorectal cancer patients [119] , particularly in the microsatellite stable patient population [120] . BRAF V600 mutations are associated with increased sensitivity to BRAF inhibitors in melanoma [121] [122] [123] [124] [125] . While BRAF V600-mutated melanomas are sensitive to BRAF inhibition, BRAF V600-mutated colorectal cancers may not be as sensitive [126] . A meta-analysis has shown an association between BRAF V600E mutation and lack of response to anti-EGFR monoclonal antibodies in patients with KRAS wild-type metastatic colorectal cancer [127] . TP53 c.817C>T (p.R273C) Class 2 The R237C mutation affects the Arginine-273 amino acid that is in contact with the phosphate backbone of DNA. This mutant retains some residual DNA binding activity [128] . The R273C variant is recurrent in many cancer types [129] . This variant has been associated with a more aggressive phenotype in in vitro studies using lung and breast cancer cell lines [129] 
Class 2 Approximately 10%À30% of colorectal cancers harbor PIK3CA mutations, of which 4.2% are PIK3CA Q546K [130] . This mutation increases the activity of PI3K and enhances tumor oncogenic potential [131] . Colorectal cancer xenograft tumors harboring the PIK3CA Q546K mutation have been shown to demonstrate response to the PI3K inhibitor,
Class 3A The E1544* variant results in premature truncation of the APC protein at position 1544 [132] . It is predicted to result in loss of protein function [133] . Loss of normal APC function is known to be an early event in both familial and sporadic colon cancer pathogenesis. APC mutations do not appear to alter the prognosis of patients with colorectal cancer. There are a number of small molecule inhibitors that target the Wnt pathway, however there is currently no available matched targeted therapy for colorectal cancer patients harboring an APC mutation [134] Class 1 mutation: This mutation is known to be actionable (druggable/predictive/prognostic) in the disease site in which it has been identified. Class 2 mutation: This finding is of uncertain significance. This mutation is known to be actionable in a different disease site and/or histology. However, in this disease site/histology, actionability has not been established. Class 3A mutation: This finding is of uncertain significance. Mutations of this gene in this site/histology have been shown to be associated with actionability. However, this specific mutation is not reported as one of the recurrent mutations. Mutation functional prediction algorithms have been employed to determine the predicted effect of the mutation on protein function, which indicate that the identified mutation probably does modify protein function [15] . IMPACT, Integrated Molecular Profiling in Advanced Cancer Trial; COMPACT, Community Oncology Molecular Profiling in Advanced Cancer Trial; PI3K, phosphoinositide 3-kinase; EGFR, epidermal growth factor receptor.
setting, the teams of experts discuss the patient's clinical history, imaging, pathology and molecular results, in context of currently available evidence and prioritize identified somatic variants for treatment matching [19, 61, 62, 65, 70] . Virtual molecular tumor boards such as the American Society of Clinical Oncology's (ASCO) Molecular Oncology Tumor Board [71] are available for clinician access, although these are directed towards clinician education and are generally not a forum to discuss patient-specific cases. Presently, referral to academic institutions with established molecular profiling programs remains the main avenue for individual patient case deliberations. A number of commercial forums are available for clinician peer-discussion of patient molecular profiling results; however, the absence of multidisciplinary involvement and input represents limitations in some cases. In addition, these discussion forums are generally limited to physicians utilizing the particular profiling service.
Patient molecular pre-selection for clinical trials
A recent meta-analysis of phase I clinical trials in oncology demonstrated significant improvements in patient outcomes with the use of biomarker-based treatment strategies compared with nonpersonalized targeted arms [72] . However, studies where biomarkers were used to pre-select patients constitute only $16% of all trials evaluated, and the results of such a retrospective evaluation can be affected by publication bias [72] . Despite the promise held by molecular selection, many molecularly targeted agents currently in development do not have sufficiently robust predictive biomarkers to be used for patient stratification.
More recently, the search for predictive biomarkers have broadened to adopt a more global view of tumor mutational burden and derivation of genetic signatures based on observed patterns of somatic variations. Examples include the association of high non-synonymous mutational burden and response to immune checkpoint inhibition in non-small cell lung cancer [73] , and smoking-related signature in head and neck cancer conferring poorer prognosis [74] . These novel approaches tend to require the use of larger gene panels or whole exome/whole genome sequencing, as targeted DNA sequencing using small panels of a limited number of genes would be insufficiently comprehensive in obtaining the required information [73, 74] .
Equitability of drug access
Access to targeted agents depends on their specific stage of development and status of registration approval. In general, clinical trials would allow access to drugs of all stages and is the most optimal way to access investigational drugs currently in clinical development. Approved drugs that qualify for government reimbursements are available for on-label use to eligible patients, or maybe available through patients' health insurance plans if covered. On-label or offlabel use of approved drugs can be obtained through clinical trials, company-specific access programs, registries, or through private payments. Drug access is further subject to region and governmentspecific laws and practices [75] . In addition to databases that offer genotype-drug matching, there are region-specific clinical trials matching resources including Canadian Cancer Trials (Canada) [76] , the National Cancer Institute's clinical trials search (USA) [77] , and Molecular Match (USA and Canada) [78] .
A number of commercial molecular profiling vendors in oncology provide recommendations for treatment and avenues for sourcing particular targeted agents, whether via on-label prescription, off-label use or enrolment into clinical trials, as part of their report. Some providers further offer services to aid with accessing targeted agents for off-label use. However, the clinical context of individual patient cases can be complex and often is not factored into automated treatment recommendations. In addition, the level of evidence supporting the reported recommendation varies and must be cautiously interpreted. Whenever possible, patients should be encouraged to enroll in clinical trials that rigorously test the hypothesis of genotype-drug matching and avoid the prescription of targeted drugs for off-label indications outside the research context.
Integrating patient outcome data from off-label use of targeted agents
Clinical trials or registries to evaluate off-label use of targeted agents to match potentially actionable mutations represent another resource to assess the clinical utility of precision oncology [79, 80] . Targeted Agent and Profiling Utilization Registry (TAPUR) study, the first clinical trial by ASCO, aims to capture this data through the provision of matched targeted anticancer drugs to patients with potentially actionable genomic variants for off-label indications (NCT02693535). As part of its services, TAPUR provides access to a Molecular Tumor Board to consult on the proposed treatment and/or alternative treatment options. Participating pharmaceutical companies provide study drugs at no cost to the patient, who is in turn followed for toxicity and efficacy outcomes. Drug Rediscovery Protocol (DRUP, EudraCT 2015-004398-33) under the auspice of the Centre for Personalized Cancer Treatment in the Netherlands and Canadian Profiling and Targeted agent Utilization tRial (CAPTUR) being planned by the Canadian Cancer Trials Group, are two initiatives with the common goal for international data amalgamation with TAPUR.
Global data sharing initiatives
Molecular characterization of tumors to enable treatment decision has become increasingly prevalent in academic and commercial institutions. However, clinically annotated genomic data are generally confined to individual institutions resulting in a phenomenon of data silos [81] . Increasing understanding of genomic variations in cancer has classified many tumors into smaller genomic subtypes, such that correlation to clinical data requires access to vast number of patients. This particularly challenges the annotation of low-frequency variants [82] . Indeed, global data sharing initiatives are of critical importance in accelerating our understanding of tumor heterogeneity and to improve the clinical applicability of molecular profiling in cancer [81] .
Somatic variant databases that allow crowdsourcing by the scientific community represent one of the earliest attempts at data unification through the voluntary sharing of data by individual or research groups. Barriers to the amalgamation of molecular profiling data include variations in detection technique, sequencing depth, extent of genome being analyzed, standardization of nomenclature to describe variants, concerns surrounding privacy and data security, as well as technological requirements for sharing of vast volumes of information. In addition, there is no standardized process for clinical outcome data collection outside the clinical trial setting. Initiatives such as GA4GH [81] , Data Sharing Task Force of Cancer Core Europe [83] , Project GENIE of the American Association for Cancer Research [84] , and Genomic Data Commons of the National Cancer Institute [85] are working to address these and create a framework for global data sharing and analysis [86] . Key molecular profiling and big data initiatives worldwide are discussed and summarized in a recent perspective by GA4GH [81] .
Future directions
Accumulation and amalgamation of large volumes of sequencing and clinical data require robust methods and infrastructure for analysis and interpretation [5] . Computational genomics is an evolving field that responds to the need for high-throughput analytical technology to analyze complex cancer gene signatures and network systems active within the cellular biochemical pathways [87] . Indeed, it is now feasible to profile thousands of individual cells from tumor tissues [88] , thereby magnifying the challenging of cancer genome interpretation. Pilot studies have shown promising results in the fields of drug repurposing and identification of novel targets through the analysis of past literature using machine learning algorithms [89] .
Modest response rates from molecular basket and umbrella trials are sobering [62, 63, 90] , indicating that we are likely close to maximizing the benefit from single-agent targeted therapies. The general lack of robust predictive biomarkers for many molecularly targeted agents under development further compounds treatment selection conundrums. Research and clinical trials in oncology are moving beyond single-agent therapies into increasingly sophisticated assessment of genomic aberrations in cancer to include interrogation of the functional non-coding genome, transcriptome and epigenome, with integration of judicious biomarker testing and formulation of biologically sound rationales for combination therapy trials [13, [91] [92] [93] [94] [95] [96] . Global efforts to harmonize variant identification and annotation will likely be the dominating theme of the next decade in cancer genome research, with hopes to accelerate the development of novel targeted therapies and their combination to improve patient outcomes [57, 81] .
